• Profile
Close

Plasma kidney injury molecule 1 in CKD: Findings from the Boston Kidney Biopsy Cohort and CRIC studies

American Journal of Kidney Diseases Jun 28, 2021

Schmidt IM, Srivastava A, Sabbisetti V, et al. - This prospective, observational cohort study was undertaken to investigate the association of plasma kidney injury molecule-1 (KIM-1), a sensitive marker of proximal tubule injury, with risks of adverse clinical results across a spectrum of kidney diseases. Participants included 524 persons undergoing clinically indicated native kidney biopsy with biopsy specimens adjudicated for semiquantitative scores of histopathology by two kidney pathologists enrolled into the Boston Kidney Biopsy Cohort (BKBC) Study as well as 3,800 people suffering from common types of chronic kidney disease enrolled into the Chronic Renal Insufficiency Cohort (CRIC) Study. More severe acute tubular injury, tubulointerstitial inflammation, and more severe mesangial expansion post- multivariable adjustment were detected in relation to higher plasma KIM-levels, in the BKBC Study. A median follow-up of 11.5 years revealed progression to renal failure in 1153 participants and deaths of 1356 participants, in the CRIC Study. Findings showed that in two cohort studies of persons with kidney diseases, there was a connection of plasma KIM-1 with underlying tubulointerstitial and mesangial lesions as well as with progression to kidney failure.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay